XML 64 R54.htm IDEA: XBRL DOCUMENT v3.25.2

Option Agreements and License Agreements (Details) - USD ($) $ in Millions	1 Months Ended	2 Months Ended	3 Months Ended		5 Months Ended	6 Months Ended	11 Months Ended	12 Months Ended
	Jul. 31, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2025	Dec. 31, 2024	Dec. 31, 2025
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments						$ 4.0
Expenses			$ 4.2	$ 15.4	$ 20.4	5.7
Paruka Warrant Obligation [Member]
Option Agreements and License Agreements [Line Items]
Warrant purchase percentage							1.00%	1.00%
ORKA-002 [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments	$ 3.0
Milestone consideration paid			2.5			2.5
Research and development expenses				$ 2.7	6.9	$ 0.1
ORKA-001 [Member]
Option Agreements and License Agreements [Line Items]
Development costs						50.00%
Research and development expenses		$ 12.4			$ 13.2
Related Party [Member] | ORKA-002 [Member]
Option Agreements and License Agreements [Line Items]
Accounts payable and other current liabilities							$ 2.7
Related Party [Member] | ORKA-001 [Member]
Option Agreements and License Agreements [Line Items]
Accounts payable and other current liabilities							$ 12.4
Paragon [Member] | Antibody Products [Member]
Option Agreements and License Agreements [Line Items]
Royalty payable on product sales, description							low single-digit percentage royalty for antibody products
Paragon [Member] | ORKA-002 [Member] | Research and Development Expense [Member] | Achievement Of Development Candidate [Member]
Option Agreements and License Agreements [Line Items]
Milestone consideration paid							$ 1.5
Paragon [Member] | ORKA-002 [Member] | Research and Development Expense [Member] | Exercising Option [Member]
Option Agreements and License Agreements [Line Items]
Nonrefundable research initiation fee							0.8
Paragon [Member] | ORKA-001 [Member]
Option Agreements and License Agreements [Line Items]
Nonrefundable research initiation fee							0.8
Paragon [Member] | ORKA-001 [Member] | Research and Development Expense [Member] | Achievement Of Development Candidate [Member]
Option Agreements and License Agreements [Line Items]
Milestone consideration paid							1.5
Paragon [Member] | ORKA-001 [Member] | Research and Development Expense [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member]
Option Agreements and License Agreements [Line Items]
Milestone consideration paid							2.5
Maximum [Member] | Paragon [Member] | Clinical Development Milestones [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments							12.0
Maximum [Member] | Paragon [Member] | Regulatory Milestones Member [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments							10.0
Maximum [Member] | Paragon [Member] | ORKA-002 [Member] | Clinical Development Milestones [Member]
Option Agreements and License Agreements [Line Items]
Non-refundable milestone payments							$ 12.0

X

- Definition

class of warrant or right to purchase percentage of outstanding diluted stock maximum.

+ References

No definition available.

+ Details

Name:	orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum
Namespace Prefix:	orka_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Development cost.

+ References

No definition available.

+ Details

Name:	orka_DevelopmentCost
Namespace Prefix:	orka_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of milestone consideration paid.

+ References

No definition available.

+ Details

Name:	orka_MilestoneConsiderationPaid
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Non refundable initiation fee.

+ References

No definition available.

+ Details

Name:	orka_NonRefundableInitiationFee
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Non-refundable milestone payments.

+ References

No definition available.

+ Details

Name:	orka_NonRefundableMilestonePayments
Namespace Prefix:	orka_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Royalty payable on product sales, description.

+ References

No definition available.

+ Details

Name:	orka_RoyaltyPayableOnProductSales
Namespace Prefix:	orka_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccountsPayableOtherCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_OtherExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=orka_ParagonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AntibodyProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AchievementOfDevelopmentCandidateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ExercisingOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: